Indeed, the success of Belimumab in the treatment of patients with RA and ongoing clinical trials in SSc (NCT01670565) suggest that therapeutic targeting of BAFF could be of interest [42]. This evidence concerns the gene TNFSF13B and rheumatoid arthritis.